BNP Paribas Financial Markets’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-172
| Closed | -$20.4K | – | 4166 |
|
|
2021
Q1 | $20.4K | Sell |
172
-11,660
| -99% | -$1.38M | ﹤0.01% | 3755 |
|
|
2020
Q4 | $1.4M | Buy |
+11,832
| New | +$1.37M | ﹤0.01% | 1812 |
|
|
2019
Q2 | – | Sell |
-10
| Closed | -$912 | – | 4654 |
|
|
2019
Q1 | $912 | Hold |
10
| – | – | ﹤0.01% | 4154 |
|
|
2018
Q4 | $759 | Hold |
10
| – | – | ﹤0.01% | 3956 |
|
|
2018
Q3 | $800 | Sell |
10
-64,000
| -100% | -$5.96M | ﹤0.01% | 4325 |
|
|
2018
Q2 | $6.36M | Sell |
64,010
-11,000
| -15% | -$950K | 0.01% | 980 |
|
|
2018
Q1 | $6.08M | Buy |
75,010
+75,000
| +750,000% | +$6.06M | 0.01% | 909 |
|
|
2017
Q4 | $788 | Hold |
10
| – | – | ﹤0.01% | 4106 |
|
|
2017
Q3 | $923 | Hold |
10
| – | – | ﹤0.01% | 4095 |
|
|
2017
Q2 | $1.13K | Hold |
10
| – | – | ﹤0.01% | 4113 |
|
|
2017
Q1 | $1K | Hold |
10
| – | – | ﹤0.01% | 3701 |
|
|
2016
Q4 | $1.07K | Sell |
10
-1,373
| -99% | -$161K | ﹤0.01% | 4013 |
|
|
2016
Q3 | $172K | Buy |
1,383
+1,343
| +3,358% | +$159K | ﹤0.01% | 1824 |
|
|
2016
Q2 | $4.25K | Sell |
40
-14,174
| -100% | -$1.65M | ﹤0.01% | 3339 |
|
|
2016
Q1 | $1.63M | Sell |
14,214
-14,288
| -50% | -$1.68M | 0.01% | 893 |
|
|
2015
Q4 | $4.06M | Buy |
28,502
+14,171
| +99% | +$1.64M | 0.01% | 703 |
|
|
2015
Q3 | $1.29M | Sell |
14,331
-38
| -0.3% | -$4.01K | ﹤0.01% | 970 |
|
|
2015
Q2 | $1.65M | Buy |
+14,369
| New | +$1.51M | ﹤0.01% | 939 |
|
BNP Paribas Financial Markets's CBPO Position: Q2 2021 in Review
BNP Paribas Financial Markets sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 172 shares — an estimated $20.4K sold.
BNP Paribas Financial Markets first reported a position in CBPO in Q2 2015 and held it in 18 quarters. The position peaked at $6.36M in Q2 2018. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- BNP Paribas Financial Markets reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 172 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $20.4K.
- BNP Paribas Financial Markets first reported a position in China Biologic Products Holdings, Inc. in Q2 2015 and held it in 18 quarters.
- BNP Paribas Financial Markets's China Biologic Products Holdings, Inc. position peaked at $6.36M in Q2 2018.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2021, filed 10 Aug 2021.